Mustang Bio's MB-106 CAR-T interim data selected for ASH; complete responses in FL

MUSTANG BIO, INC.

Interim Phase 1/2 data for MB-106 (CD20-targeted CAR-T) accepted as poster at ASH Dec 9-12, 2023.
At dose level 1 (3.3x10^6 cells/kg): two FL patients achieved complete response, WM patient VGPR, HCL-v stable disease with transfusion independence.
Safety: 3 patients Grade 1 CRS, no ICANS or dose-limiting toxicities; outpatient infusion allowed.
Patients heavily pre-treated (median 5.5 prior lines); WM patient had nine prior treatments including auto-SCT.
Pivotal Phase 2 WM trial expected to start mid-2024 with top-line data possible by mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.